Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO
Phase of Trial: Phase I/II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema
- Focus Adverse reactions
- Sponsors Taiwan Liposome Company
- 11 Apr 2019 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.
- 20 Aug 2018 A new treatment group "TLC399- Group R1 " has been added, study design has changed form parallel assignment to single group assignment hence, the protocol was amended.
- 20 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2020.